At such moments, you must cross your fingers behind your back and say: “Tax cuts pay for themselves.” In such fashion, ...

Despite a marginal revenue increase of just over 1 per cent from Rs 659.99 crore in Q4 FY24 to Rs 666.96 crore in Q4 FY25 -- higher expenses across raw materials, employee costs, finance charges ...

ImmunityBio earned net product revenue of approximately $16.5 million during the three-month period ended March 31, 2025, which represented an increase of 129% over the $7.2 million of net revenue ...

And by the way, when I talked about producing $250 million in revenue in a calendar quarter by the end of 2027, this is the type of product given the success we're seeing in this program ...

Leveraging our deep expertise in networking and security convergence, a strong track record of AI-driven innovation and seamless product development ... cyber security.” Revenue in the range ...

For the three months ended March 31, 2025—marking the first quarter with a permanent J-code that streamlined billing and reimbursement for prescribing providers—ImmunityBio achieved net product ...